CR20230365A - Antagonistas de gitr y métodos de uso de los mismos - Google Patents

Antagonistas de gitr y métodos de uso de los mismos

Info

Publication number
CR20230365A
CR20230365A CR20230365A CR20230365A CR20230365A CR 20230365 A CR20230365 A CR 20230365A CR 20230365 A CR20230365 A CR 20230365A CR 20230365 A CR20230365 A CR 20230365A CR 20230365 A CR20230365 A CR 20230365A
Authority
CR
Costa Rica
Prior art keywords
methods
same
gitr antagonists
compounds
gitr
Prior art date
Application number
CR20230365A
Other languages
English (en)
Inventor
Stacey Lynn Lee
Mark Andrew Wortinger
Petra Verdino
Paul Francis Cain
Melinda Ann Lacerte
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20230365A publication Critical patent/CR20230365A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente descripción se refiere a compuestos que se unen al GITR humano, composiciones farmacéuticas que comprenden tales compuestos y métodos de uso de tales compuestos.La presente descripción se refiere a compuestos que se unen al GITR humano, composiciones farmacéuticas que comprenden tales compuestos y métodos de uso de tales compuestos.
CR20230365A 2021-02-02 2022-02-01 Antagonistas de gitr y métodos de uso de los mismos CR20230365A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144732P 2021-02-02 2021-02-02
US202263297968P 2022-01-10 2022-01-10
PCT/US2022/014752 WO2022169766A1 (en) 2021-02-02 2022-02-01 Gitr antagonists and methods of using the same

Publications (1)

Publication Number Publication Date
CR20230365A true CR20230365A (es) 2023-09-08

Family

ID=80787518

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230365A CR20230365A (es) 2021-02-02 2022-02-01 Antagonistas de gitr y métodos de uso de los mismos

Country Status (17)

Country Link
US (2) US11859005B2 (es)
EP (1) EP4288097A1 (es)
JP (1) JP7728873B2 (es)
KR (1) KR102856892B1 (es)
AU (1) AU2022216230A1 (es)
CA (1) CA3205852A1 (es)
CL (1) CL2023002288A1 (es)
CO (1) CO2023009885A2 (es)
CR (1) CR20230365A (es)
DO (1) DOP2023000143A (es)
EC (1) ECSP23058279A (es)
IL (1) IL304434A (es)
JO (1) JOP20230174A1 (es)
MX (1) MX2023009007A (es)
PE (1) PE20240914A1 (es)
TW (1) TW202246334A (es)
WO (1) WO2022169766A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL327830A (en) 2023-10-18 2026-06-01 Lilly Co Eli Transferrin receptor binding proteins and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN02826A (es) 2009-09-03 2015-09-11 Merck Sharp & Dohme
PH12012501744A1 (en) * 2010-03-03 2021-08-09 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
CN108610421B (zh) * 2012-02-27 2022-08-19 阿布林克斯有限公司 Cx3cr1结合多肽
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
AU2016364895A1 (en) 2015-12-02 2018-06-07 Agenus Inc. Anti-GITR antibodies and methods of use thereof
WO2017096276A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
MX2018010851A (es) * 2016-03-08 2019-02-07 Janssen Biotech Inc Anticuerpos de gitr, métodos, y usos.
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
KR20190112299A (ko) * 2017-01-27 2019-10-04 울트라휴먼 원 리미티드 결합제
US11198735B2 (en) * 2017-03-03 2021-12-14 Rinat Neuroscience Corp. Anti-GITR antibodies and methods of use thereof
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
WO2018176159A1 (en) * 2017-03-31 2018-10-04 Zymeworks Inc. Tumor antigen presentation inducer constructs and uses thereof

Also Published As

Publication number Publication date
KR20230122171A (ko) 2023-08-22
AU2022216230A1 (en) 2023-07-20
TW202246334A (zh) 2022-12-01
PE20240914A1 (es) 2024-04-30
EP4288097A1 (en) 2023-12-13
JP7728873B2 (ja) 2025-08-25
AU2022216230A9 (en) 2024-10-10
US11859005B2 (en) 2024-01-02
DOP2023000143A (es) 2023-09-15
US20240158525A1 (en) 2024-05-16
MX2023009007A (es) 2023-08-08
JOP20230174A1 (ar) 2023-07-30
ECSP23058279A (es) 2023-09-29
CL2023002288A1 (es) 2024-02-02
CO2023009885A2 (es) 2023-08-09
KR102856892B1 (ko) 2025-09-10
US20220251227A1 (en) 2022-08-11
WO2022169766A1 (en) 2022-08-11
CA3205852A1 (en) 2022-08-11
IL304434A (en) 2023-09-01
JP2024505563A (ja) 2024-02-06

Similar Documents

Publication Publication Date Title
MY208549A (en) Parp1 inhibitors
MY200356A (en) Kras g12c inhibitors
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2021015761A (es) Polipeptidos.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MY209035A (en) Tricyclic compounds and their use
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
MY196791A (en) New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions
MX2024001644A (es) Anticuerpos contra el receptor alfa de la interleucina-4 humana.
MX2020010568A (es) Derivados de urea ciclica fusionada como antagonista de crhr2.
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
PH12021552133A1 (en) Aromatic derivatives, preparation methods, and medical uses thereof
MX2024012565A (es) Composiciones farmaceuticas de mosunetuzumab y metodos de uso
ZA202102816B (en) High concentration protein formulation
ZA202401405B (en) Compositions and methods for anti-pacap antibodies
WO2019103875A3 (en) Methods of using and compositions containing dulaglutide
EA202191378A1 (ru) Активные сложноэфирные производные тестостерона, их композиции и применения
JOP20230174A1 (ar) مضادات gitr وطرق استخدامها